Who’s who in Big Pharma offers appetizing look at ASCO data

Tracy Staton With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released ...

Roche’s next-gen Rituxan candidate impresses in first look at PhIII data

John Carroll Roche got a big boost for its bid to position the leukemia drug GA101 (obinutuzumab) as a next-gen successor to its blockbuster Rituxan, posting late-stage data last night ...

Gilead speeds ahead on idelalisib with promising leukemia data

John Carroll Gilead may be best known for its HIV drug franchise and a stellar late-stage effort on the hepatitis C front, but the big biotech is also making an ambitious bid to rapidly ...

GlaxoSmithKline’s ‘independent experts’ start to hand out keys to its data vault

John Carroll Despite a major backlash in the industry, GSK has agreed to open up the data vault to investigators who intend to publish their findings, accelerating a move in the industry ...

Celgene nabs another round of promising pivotal apremalist data for psoriatic arthritis

John Carroll FierceBiotech News

Bristol-Myers, AstraZeneca report positive data for rare metabolic disease drug

John Carroll The treatment, under review at the FDA, was acquired by Bristol-Myers Squibb as part of its $ 5.3 billion acquisition of Amylin last year and swiftly partnered with AstraZeneca ...

Allergan slams brakes on two key PhIIIs after data disappoints

John Carroll Allergan has slammed the brakes on two planned late-stage studies of a pair of key therapeutics in its pipeline, saying that investigators have to go back to the mid-stage ...

EMA vows to battle AbbVie in courts for full data transparency

John Carroll AbbVie ($ ABBV) and InterMune ($ ITMN) may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs. But the powerful ...

Eli Lilly scores upbeat PhIII data for GLP1 drug in busy diabetes market

Ryan McBride Eli Lilly ($ LLY) has added to a body of positive Phase III data for its once-weekly GLP-1 candidate dulaglutide, with two more late-stage studies that have met their ...

FDA seeks more data from Sarepta to decide on accelerated approval

Ryan McBride Sarepta Therapeutics ($ SRPT) has kept hopes alive for gaining accelerated approval for its lead drug eteplirsen for Duchenne muscular dystrophy. Yet the FDA wants additional ...

Report slams FDA’s response to CRO’s fraudulent study data

Ryan McBride The FDA is feeling the sting from defunct Cetero Research's fraudulent drug trial data nearly three years after investigators raided the CRO's Houston labs. ProPublica ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS